Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Diverse molecular pathways in ovarian cancer and their clinical significance|
|Citation:||Maturitas, 2009; 62(3):270-275|
|Publisher:||Elsevier Sci Ireland Ltd|
|Carmela Ricciardelli, Martin K. Oehler|
|Abstract:||The origin of epithelial ovarian cancer remains unknown. It is believed to develop from ovarian surface epithelium, post-ovulatory inclusion cysts, endometriosis and more recently the fimbrial end of the fallopian tube. Molecular evidence suggests that ovarian cancer may progress both through a step-wise mutation process (low-grade pathway, type I), and a separate pathway with high genetic instability leading to rapid metastasis without an identifiable precursor lesion (high-grade pathway, type II). This sub-classification explains the clinical and biological heterogeneity of ovarian cancer and highlights the importance for developing novel diagnostics and therapeutics targeting two unique diseases-type I and type II ovarian carcinomas. This article summarises current knowledge of the aetiology and molecular basis of ovarian cancer and discusses recent clinical strategies for type I and type II disease.|
|Keywords:||BRCA; Early detection; Fallopian tube; Molecular pathology; Ovarian cancer; PARP inhibitors; Peritoneal cancer; Two-pathway concept|
|Description:||Copyright © 2009 Elsevier Ireland Ltd All rights reserved.|
|Appears in Collections:||Obstetrics and Gynaecology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.